Ignite Creation Date:
2024-05-05 @ 11:26 PM
Last Modification Date:
2024-10-26 @ 10:34 AM
Study NCT ID:
NCT01337752
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2011-04-12
Brief Title:
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Double-blind Placebo-controlled Randomized Phase 2 Study of BHQ880 an Anti-Dickkopf1 DKK1 Monoclonal Antibody mAb in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status:
COMPLETED
Status Verified Date:
2020-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy The primary objective of the study will be to evaluate the effect of BHQ880 in combination with bortezomib and dexamethasone compared to placebo administered with the combination on the time to first Skeletal Related Event SRE on study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2009-010875-26 | EUDRACT_NUMBER | None | None |